Chantilly BioPharma LLC. logo
 
Chantilly BioPharma (CBL) is engaged in the development, manufacturing, commercialization, licensing and marketing of its proprietary technologies and products for a wide range of pharmaceuticals.
CBL’s primary focus is on the commercialization of products incorporating its SmartCoat®, KORTABS®, KOR-BEADS, CEATRIXXTM, Ceform-MR, KORLAYER, Flash Dose®, RAPIDMELT, FLASHBEADS®, Shearform®, CE-SPHERESTM, CE-CAPSTM and Ceform TI technologies for use inmicrosphere processing, modified release drug delivery, orally disintegrating tablets and drug solubility/ bioenhancement.
The Company has a state-of-the-art facility with up-to-date Quality Assurance systems for manufacturing, analytical testing and packaging of prescription products.
The Company is registered with FDA, DEA and other appropriate regulatory authorities.
Business Development Services include out-licensing of pipeline products, in-licensing of new product opportunities, partnered product development and pharmaceutical contract services.
  • CBL is one of the sponsors for PODD event.

  • Chantilly BioPharma Offers Proprietary Drug Delivery Technologies.

  • CBL has in-licensed 6 patents, products and trademarks for commercialization.

  • Chantilly Biopharma announces asset acquisition from Valeant Pharmaceutical International Inc.